You are here

valrox

BioMarin talks down worries on gene therapy data differences

BioMarin talks down worries on gene therapy data differences

Biopharma Dive

Flag link:

BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end

BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end

Fierce Biotech

valoctocogene roxaparvovec

Flag link:

How BioMarin May Revolutionize the Hemophilia Treatment Market

How BioMarin May Revolutionize the Hemophilia Treatment Market

Motley Fool

Flag link:

Two drugs in the pipeline representing unique marketing challenges

Two drugs in the pipeline representing unique marketing challenges

Medical Marketing and Media

Boehringer Ingelheim

Flag link:

Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study

Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study

Endpoints

Flag link: